[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abdominal-sepsis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abdominal-sepsis":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100602754",false,"NCT07127627","Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography\u002FComputed Tomography","Characterization of Abdomino-pelvic Lesions in Cancer Patients by 18F-FDG PET\u002FCT","18F-FDG PET\u002FCT","Inclusion Criteria:\n\n* Inclusion criteria: All of the patients were suspected of having malignancy (new, recurrent or metastatic) based on pathology or conventional radiological studies and were referred to nuclear medicine unit for 18F-FDG-PET-CT scan\n\nExclusion Criteria:\n\n* patients underwent recent abdominal or pelvic surgery.\n* patients with blood glucose level ˃200 mg\u002FdL\n* Pregnancy","ALL",{"count":18,"type":19},79,"ESTIMATED","OBSERVATIONAL","The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET\u002FCT) scan, including determining their malignant or benign nature, and to determine the extent of disease to facilitate proper management",[23],"Abdominal Sepsis",[25],"abdominopelvic lesions","NOT_YET_RECRUITING","2025-08-14",{"date":29,"type":30},"2025-08-17","ACTUAL",{"date":32,"type":19},"2025-08",{"date":34,"type":19},"2028-11",{"name":36,"class":37},"Assiut University","OTHER",{"id":39,"slug":4,"hasResults":10,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100554840","NCT06504316","OXiris for Abdominal SEptic Shock (OASES Study)","A Multicenter, Randomized Control Clinical Trial on the Effect of Adsorptive Filter oXiris on Hemodynamics of Abdominal Septic Shock Patients","OASES","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Weight ≥30 kg;\n3. Intra-abdominal infection (blood or abdominal drainage fluid culture positive for Gram-negative bacteria or suspected to be caused by a Gram-negative agent);\n4. Diagnostic septic shock (Sepsis 3.0): Sepsis was defined as \"life-threatening organ dysfunction caused by a dysregulated host response to infection\" with organ dysfunction defined as an increase in qSOFA ⩾2 points. Septic shock was defined as sepsis requiring vasoactive therapy to maintain mean arterial pressure (MAP) ⩾ 65 mmHg and lactate elevation to \\>2 mmol\u002FL despite adequate volume resuscitation;\n5. The dose of norepinephrine⩾0.4ug\u002Fkg\u002Fmin;\n6. PCT⩾50ug\u002FL, and\u002For IL-6⩾1000pg\u002Fml;\n7. AKI stage II\u002FIII (Kidney Disease Improving Global Outcomes, KDIGO grade);\n8. Duration of septic shock ≤48 hours.\n\nExclusion Criteria:\n\n1. Patients with highly contagious infectious diseases, such as tuberculosis;\n2. Pregnant and lying-in woman or lactation period;\n3. Infection of other sites (no abdominal infection like pneumonia, central nervous system infection and so on);\n4. CRRT cannot be performed for various reasons;\n5. Death is expected within 48 hours of admission to the ICU;\n6. Previous renal replacement therapy;\n7. Patients that underwent cardio-pulmonary resuscitation (CPR);\n8. Patients who will not sign the informed consent form.","18 Years",{"count":47,"type":19},192,"INTERVENTIONAL",[50],"NA","This study innovatively utilizes multi-modal hemodynamic monitoring (Norepinephrine equivalence, NEE+Pulse indicator Continuous Cariac output, PiCCO) to investigate the optimal timing of initiation of oXiris in abdominal infection-associated septic shock patients and to investigate prognosis on sepsis phenotypes undergoing oXiris therapy.",[53,23,54,55,56],"Septic Shock","Multi Organ Failure","Blood Purification","AKI - Acute Kidney Injury","2024-07-10",{"date":59,"type":30},"2024-07-16",{"date":61,"type":19},"2024-08-15",{"date":63,"type":19},"2027-05-31",{"name":65,"class":37},"RenJi Hospital",1,""]